Pharmaceutical Technology on MSN

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.
MarketBeat on MSN

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio's Volatile Week Puts Biotech Stocks Under a Microscope BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA ...
manilatimes

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White

- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes1 "In clinical practice, ATTR-CM is ...
STAT

BridgeBio wins FDA approval for heart disease drug

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Nasdaq

BridgeBio Pharma Reports Significant Launch Progress for Attruby™ Following FDA Approval and EU Marketing Authorization

1,028 unique patient prescriptions for Attruby™ have been written by 516 unique prescribers since FDA approval, indicating strong initial market uptake. Attruby™ is the first and only near-complete ...